Molecular and immunological evaluation of the expression of cancer/testis gene products in human colorectal cancer

Sebastien Viatte; Pedro M S Alves; Nicole Lévy; Hanifa Bouzourene; Sébastien Viatte; Gabriel Bricard; Maha Ayyoub; Henri Vuilleumier; Jean Claude R Givel; Nermin Halkic; Daniel E. Speiser; Pedro Romero; Frédéric Lévy

doi:10.1007/s00262-006-0228-5

Molecular and immunological evaluation of the expression of cancer/testis gene products in human colorectal cancer

Sebastien Viatte, Pedro M S Alves, Nicole Lévy, Hanifa Bouzourene, Sébastien Viatte, Gabriel Bricard, Maha Ayyoub, Henri Vuilleumier, Jean Claude R Givel, Nermin Halkic, Daniel E. Speiser, Pedro Romero, Frédéric Lévy

Research output: Contribution to journal › Article › peer-review

Abstract

Tumor-specific gene products, such as cancer/testis (CT) antigens, constitute promising targets for the development of T cell vaccines. Whereas CT antigens are frequently expressed in melanoma, their expression in colorectal cancers (CRC) remains poorly characterized. Here, we have studied the expression of the CT antigens MAGE-A3, MAGE-A4, MAGE-A10, NY-ESO-1 and SSX2 in CRC because of the presence of well-described HLA-A2-restricted epitopes in their sequences. Our analyses of 41 primary CRC and 14 metastatic liver lesions confirmed the low frequency of expression of these CT antigens. No increased expression frequencies were observed in metastatic tumors compared to primary tumors. Histological analyses of CRC samples revealed heterogeneous expression of individual CT antigens. Finally, evidence of a naturally acquired CT antigen-specific CD8+ T cell response could be demonstrated. These results show that the expression of CT antigens in a subset of CRC patients induces readily detectable T cell responses. © 2006 Springer-Verlag.

Original language	English
Pages (from-to)	839-847
Number of pages	8
Journal	Cancer Immunology, Immunotherapy
Volume	56
Issue number	6
DOIs	https://doi.org/10.1007/s00262-006-0228-5
Publication status	Published - Jun 2007

Keywords

Cancer-testis antigen
Colorectal cancer
T cell response

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00262-006-0228-5

Cite this

Viatte, S., Alves, P. M. S., Lévy, N., Bouzourene, H., Viatte, S., Bricard, G., Ayyoub, M., Vuilleumier, H., Givel, J. C. R., Halkic, N., Speiser, D. E., Romero, P., & Lévy, F. (2007). Molecular and immunological evaluation of the expression of cancer/testis gene products in human colorectal cancer. Cancer Immunology, Immunotherapy, 56(6), 839-847. https://doi.org/10.1007/s00262-006-0228-5

@article{0cff1295d848457b949550507d4139cb,

title = "Molecular and immunological evaluation of the expression of cancer/testis gene products in human colorectal cancer",

abstract = "Tumor-specific gene products, such as cancer/testis (CT) antigens, constitute promising targets for the development of T cell vaccines. Whereas CT antigens are frequently expressed in melanoma, their expression in colorectal cancers (CRC) remains poorly characterized. Here, we have studied the expression of the CT antigens MAGE-A3, MAGE-A4, MAGE-A10, NY-ESO-1 and SSX2 in CRC because of the presence of well-described HLA-A2-restricted epitopes in their sequences. Our analyses of 41 primary CRC and 14 metastatic liver lesions confirmed the low frequency of expression of these CT antigens. No increased expression frequencies were observed in metastatic tumors compared to primary tumors. Histological analyses of CRC samples revealed heterogeneous expression of individual CT antigens. Finally, evidence of a naturally acquired CT antigen-specific CD8+ T cell response could be demonstrated. These results show that the expression of CT antigens in a subset of CRC patients induces readily detectable T cell responses. {\textcopyright} 2006 Springer-Verlag.",

keywords = "Cancer-testis antigen, Colorectal cancer, T cell response",

author = "Sebastien Viatte and Alves, {Pedro M S} and Nicole L{\'e}vy and Hanifa Bouzourene and S{\'e}bastien Viatte and Gabriel Bricard and Maha Ayyoub and Henri Vuilleumier and Givel, {Jean Claude R} and Nermin Halkic and Speiser, {Daniel E.} and Pedro Romero and Fr{\'e}d{\'e}ric L{\'e}vy",

year = "2007",

month = jun,

doi = "10.1007/s00262-006-0228-5",

language = "English",

volume = "56",

pages = "839--847",

journal = "Cancer Immunology, Immunotherapy",

issn = "0340-7004",

publisher = "Springer Nature",

number = "6",

}

Viatte, S, Alves, PMS, Lévy, N, Bouzourene, H, Viatte, S, Bricard, G, Ayyoub, M, Vuilleumier, H, Givel, JCR, Halkic, N, Speiser, DE, Romero, P & Lévy, F 2007, 'Molecular and immunological evaluation of the expression of cancer/testis gene products in human colorectal cancer', Cancer Immunology, Immunotherapy, vol. 56, no. 6, pp. 839-847. https://doi.org/10.1007/s00262-006-0228-5

TY - JOUR

T1 - Molecular and immunological evaluation of the expression of cancer/testis gene products in human colorectal cancer

AU - Viatte, Sebastien

AU - Alves, Pedro M S

AU - Lévy, Nicole

AU - Bouzourene, Hanifa

AU - Viatte, Sébastien

AU - Bricard, Gabriel

AU - Ayyoub, Maha

AU - Vuilleumier, Henri

AU - Givel, Jean Claude R

AU - Halkic, Nermin

AU - Speiser, Daniel E.

AU - Romero, Pedro

AU - Lévy, Frédéric

PY - 2007/6

Y1 - 2007/6

N2 - Tumor-specific gene products, such as cancer/testis (CT) antigens, constitute promising targets for the development of T cell vaccines. Whereas CT antigens are frequently expressed in melanoma, their expression in colorectal cancers (CRC) remains poorly characterized. Here, we have studied the expression of the CT antigens MAGE-A3, MAGE-A4, MAGE-A10, NY-ESO-1 and SSX2 in CRC because of the presence of well-described HLA-A2-restricted epitopes in their sequences. Our analyses of 41 primary CRC and 14 metastatic liver lesions confirmed the low frequency of expression of these CT antigens. No increased expression frequencies were observed in metastatic tumors compared to primary tumors. Histological analyses of CRC samples revealed heterogeneous expression of individual CT antigens. Finally, evidence of a naturally acquired CT antigen-specific CD8+ T cell response could be demonstrated. These results show that the expression of CT antigens in a subset of CRC patients induces readily detectable T cell responses. © 2006 Springer-Verlag.

AB - Tumor-specific gene products, such as cancer/testis (CT) antigens, constitute promising targets for the development of T cell vaccines. Whereas CT antigens are frequently expressed in melanoma, their expression in colorectal cancers (CRC) remains poorly characterized. Here, we have studied the expression of the CT antigens MAGE-A3, MAGE-A4, MAGE-A10, NY-ESO-1 and SSX2 in CRC because of the presence of well-described HLA-A2-restricted epitopes in their sequences. Our analyses of 41 primary CRC and 14 metastatic liver lesions confirmed the low frequency of expression of these CT antigens. No increased expression frequencies were observed in metastatic tumors compared to primary tumors. Histological analyses of CRC samples revealed heterogeneous expression of individual CT antigens. Finally, evidence of a naturally acquired CT antigen-specific CD8+ T cell response could be demonstrated. These results show that the expression of CT antigens in a subset of CRC patients induces readily detectable T cell responses. © 2006 Springer-Verlag.

KW - Cancer-testis antigen

KW - Colorectal cancer

KW - T cell response

U2 - 10.1007/s00262-006-0228-5

DO - 10.1007/s00262-006-0228-5

M3 - Article

C2 - 16960690

SN - 0340-7004

VL - 56

SP - 839

EP - 847

JO - Cancer Immunology, Immunotherapy

JF - Cancer Immunology, Immunotherapy

IS - 6

ER -

Molecular and immunological evaluation of the expression of cancer/testis gene products in human colorectal cancer

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this